Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)

NCT07418034 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT07418034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07418034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
May 31, 2033
Enrollment
132 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck squamous cell cancer, head and neck squamous cell carcinoma, hpv (human papillomavirus)-associated carcinoma, hpv 16 positive oropharyngeal tumors (opc), hpv positive oropharyngeal squamous cell carcinoma, oropharyngeal cancer, oropharyngeal carcinoma, oropharyngeal human papillomavirus-positive squamous cell carcinoma, oropharyngeal squamous cell cancer, oropharyngeal squamous cell carcinoma, oropharyngeal squamous cell carcinoma (opscc), oropharyngeal squamous cell carcinoma (opscca), oropharyngeal squamous cell carcinoma (scc)